Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? (Q30426407)

21 June 2017

1 reference

title

Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? (English)

1 reference

21 June 2017

1 reference

1 reference

2

Silvio E Inzucchi

1 reference

21 June 2017

Sachin K Majumdar

1

1 reference

21 June 2017

25 January 2013

1 reference

21 June 2017

1 reference

21 June 2017

44

1 reference

21 June 2017

47-58

1 reference

21 June 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s12020-013-9884-3

21 June 2017

0 references

cites work

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Type 2 diabetes: principles of pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Lipid-induced insulin resistance: unravelling the mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Regulation of cancer cell metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Obesidomics: contribution of adipose tissue secretome analysis to obesity research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Islet beta cell failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Peroxisome proliferator-activated receptor alpha target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

PPAR delta: a dagger in the heart of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Biology of human sodium glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Dapagliflozin for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The Sweet Pee model for Sglt2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

GPR40 is expressed in glucagon producing cells and affects glucagon secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Physiological Functions of Glucocorticoids in Stress and Their Relation to Pharmacological Actions*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Diabetes in Cushing syndrome: basic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glucose metabolism in patients with subclinical Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Cell-specific roles of glucokinase in glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Immunohistochemical evidence for the presence of glucokinase in the gonadotropes and thyrotropes of the anterior pituitary gland of rat and monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glucokinase (GCK) mutations in hyper- and hypoglycemia: Maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glucokinase activators for diabetes therapy: May 2010 status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Assessing the potential of glucokinase activators in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Late sodium current inhibition as a new cardioprotective approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Rational design, synthesis, and potency of N-substituted indoles, pyrroles, and triarylpyrazoles as potential fructose 1,6-bisphosphatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Hepatic fructose-1,6-diphosphatase deficiency. A cause of lactic acidosis and hypoglycemia in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The two faces of PTP1B in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Fatty acid metabolism: target for metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Inhibitors of mammalian acetyl-CoA carboxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Glucagon and regulation of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9884-3

Adipokines in inflammation and metabolic disease

21 January 2018

1 reference

12 December 2020

The free fatty acid receptor GPR40 generates excitement in pancreatic beta-cells

1 reference

12 December 2020

Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut.

1 reference

12 December 2020

11 beta-Hydroxysteroid dehydrogenase

1 reference

12 December 2020

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme

1 reference

12 December 2020

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

1 reference

12 December 2020

On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate

1 reference

12 December 2020

Potential remains for PPAR-targeted drugs

1 reference

12 December 2020

Cortisol Secretion in Patients With Type 2 Diabetes: Relationship with chronic complications

1 reference

12 December 2020

Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone

1 reference

12 December 2020

Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.

1 reference

12 December 2020

10.1007/S12020-013-9884-3

Identifiers

DOI

1 reference

release_7ims24ubjjdprcntuhywyhr35a

21 June 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7ims24ubjjdprcntuhywyhr35a

24 November 2022

mapped directly with Wikidata item

PubMed ID

23354728

1 reference

PubMed ID

23354728